Single brain metastasis
- 1 February 2001
- journal article
- Published by Springer Nature in Current Treatment Options in Neurology
- Vol. 3 (1), 89-99
- https://doi.org/10.1007/s11940-001-0027-4
Abstract
The management of single brain metastases has evolved substantially over the last decade. The advent of triple-dose contrast-enhanced MRI scans has improved the radiologists’ capacity to resolve small tumors, and, thereby, has resulted in a declining percentage of brain metastases classified as single. Only 25% to 30% of brain metastases are single; single brain metastases in the absence of systemic metastases are termed solitary. Randomized trials suggest that patients not in imminent danger of herniation are best managed initially with dexamethasone 2 to 4 mg administered orally twice daily. The routine use of prophylactic anticonvulsants is discouraged. Patients with refractory progressive systemic tumor likely to prove fatal within 3 to 6 months should receive fractionated whole brain radiotherapy. Patients with highly radiosensitive primary tumors such as small cell lung cancer, lymphoma, and germinoma should also receive whole brain radiotherapy. Patients with inactive or controllable systemic cancer and good performance status benefit from the addition of local strategies like surgery or radiosurgery to whole brain radiotherapy. Although surgery and radiosurgery have not been compared in a randomized controlled trial, data suggest that results are similar. Consequently, for most metastases that fall within the size constraints of radiosurgery (3.5 cm or smaller in diameter), radiosurgery is preferred for its relatively noninvasive nature. Patients with larger or cystic tumors, with obstructive hydrocephalus, or neurologic instability despite corticosteroids are best treated with craniotomy. Fractionated whole brain radiation following surgical or radiosurgical management of single brain metastasis appears to decrease the risk of recurrent brain metastasis, although it has not been shown to improve survival. We recommend its use in most patients, although patients with tumors likely to be highly resistant to fractionated radiotherapy or at high risk of radiation neurotoxicity may reasonably defer its use.Keywords
This publication has 44 references indexed in Scilit:
- Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes?International Journal of Radiation Oncology*Biology*Physics, 2000
- Stereotactic radiosurgery for brainstem metastasesJournal of Neurosurgery, 1999
- Identification of prognostic factors in patients with brain metastases: a review of 1292 patientsInternational Journal of Radiation Oncology*Biology*Physics, 1999
- Postoperative Radiotherapy in the Treatment of Single Metastases to the BrainJAMA, 1998
- Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trialsInternational Journal of Radiation Oncology*Biology*Physics, 1997
- Surgery versus radiosurgery in the treatment of brain metastasisJournal of Neurosurgery, 1996
- Therapy of venous thromboembolism in patients with brain metastasesCancer, 1994
- A Randomized Trial of Surgery in the Treatment of Single Metastases to the BrainNew England Journal of Medicine, 1990
- Radiation‐induced dementia in patients cured of brain metastasesNeurology, 1989
- Identification of an optimal subgroup for treatment evaluation of patients with brain metastases using rtog study 7916International Journal of Radiation Oncology*Biology*Physics, 1989